Pulsed Radiofrequency Versus Pulsed Dose for Shoulder Pain
|ClinicalTrials.gov Identifier: NCT01561638|
Recruitment Status : Completed
First Posted : March 23, 2012
Last Update Posted : March 17, 2015
|Condition or disease||Intervention/treatment||Phase|
|Unilateral Chronic Shoulder Pain Bilateral Chronic Shoulder Pain||Procedure: Conventional Radiofrequency Procedure: Pulsed Dose Radiofrequency Procedure: Sham||Phase 1 Phase 2|
Pain scores on visual analog scale (VAS) of 0_10 before and two hours immediately after radiofrequency lesioning and at 30 , 60, 90 day after procedure. Along with Oxford shoulder score (OSS) is a 12-item patient-reported specifically designed and developed for assessing outcomes of shoulder surgery e.g. for assessing the impact on patients' quality of life of degenerative conditions such as arthritis and rotator cuff problems. . The reduction in medications and the number of complications associated with the technique will be assessed.
Diagnostic suprascapular nerve block will done by 1.0 ml of 0.5% bupivacaine under fluoroscopic guidance using non-ionized dye (iohexol). Pain reduction more than 50% based on mean VAS assessment for at least three hours consider diagnostic.
Machine used is,(NeuroTherm 1100) RF lesion generator. The standard radiofrequency technique used, patient in sitting position , non-invasive blood pressure and peripheral oxygen saturation will monitored with non invasive pulse oxymetry. Vascular peripheral intravenous routes will opened shoulder region exposed and under complete aseptic technique skin will be anesthetized with 2.0 ml of 2% lidocaine at puncture site, suprascapular notch was identified. The landmark to guide the initial entry point was a line drawn along the length of the scapular spine, bisected with a vertical line from the angle of the scapula. A radiofrequency needle was introduced through the skin, 2.5 cm along the line of the spine in the upper outer quadrant, and then guided to the edge of the suprascapular notch by use of C_arm guide fluoroscopy with the image intensifier (22-gauge, 50-mm needle; 5-mm active tip) The nerve was located accurately by stimulating at 2 Hz (threshold < 0.5 V). PRF was applied for 120 seconds 2 or 3 times (NeuroTherm radiofrequency lesion generator) creating a tingling and paresthesia felt in the dermatomal distribution of the nerve in question. Motor stimulation (2 HZ). Impedances were checked to ensure a complete electrical circuit and range from 200 to 400 Ohms, if impedance is > 400 1 ml of 1% lidocaine will be injected.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Pulsed Radiofrequency Versus New Technique "Pulsed Dose" in Treatment of Chronic Shoulder Pain|
|Study Start Date :||June 2013|
|Primary Completion Date :||March 2014|
|Study Completion Date :||April 2014|
Active Comparator: group p
pulse radiofrequency lesioning
Procedure: Conventional Radiofrequency
pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
Placebo Comparator: sham group
will receive puncture for 4 minutes
Active Comparator: group C
Pulse dose radiofrequency
Procedure: Pulsed Dose Radiofrequency
pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
- Pain [ Time Frame: up to 3 months from the procedure ]reduction of pain immediately and one ,two, and three month .after procedure
- Side effects [ Time Frame: up to12 weeks after the procedure ]Assessment of short term side effects and persisting side effects such as nausea, headache, momentary increase in pain, fever, tingling, itching, chest pain and/or burning skin at point of treatment
- Shoulder Symptoms [ Time Frame: up to12 weeks from the procedure ]Patient Self-Assessment of Shoulder Symptoms Before and After procedure Subjective symptoms would be recorded before procedure, and two hours after procedure, at four weeks, eight weeks, and twelve weeks.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561638
|Mansoura University Hospitals|
|Mansoura, DK, Egypt, 050|